Synthetic biology sits at the convergence of molecular biology, computer science, and engineering. Unlike traditional genetic engineering, which typically modifies one or two genes, synthetic biology aims to design entire biological systems from the ground up using standardized, modular components. The field emerged in the early 2000s with foundational work on genetic toggle switches and oscillators, and has since grown into a multi-billion-dollar industry spanning therapeutics, agriculture, materials, and food.
Companies like Ginkgo Bioworks have built horizontal platforms that treat organism engineering as a scalable service, operating large-scale biofoundries that automate the design-build-test-learn cycle. Twist Bioscience has driven down the cost of synthetic DNA, making it feasible to construct entire genomes from scratch. Meanwhile, startups across the ecosystem are applying synthetic biology to problems ranging from precision fermentation of proteins to engineered cell therapies for cancer.
The maturation of enabling technologies has accelerated the field dramatically. DNA synthesis costs have fallen by orders of magnitude over the past two decades, while advances in CRISPR gene editing, high-throughput screening, and machine learning for protein design have expanded what is possible. Organizations like the iGEM Foundation continue to grow the community through annual competitions, and governments worldwide have published national bioeconomy strategies recognizing synthetic biology as a strategic technology for the 21st century.